405937-99-7

Basic information

• Product Name: (E)-3-(3,5-difluorophenyl)acrylaldehyde
• Synonyms: (E)-3-(3,5-difluorophenyl)acrylaldehyde
• CAS NO: 405937-99-7
• Molecular Weight: 168.143
• Mol File: 405937-99-7.mol
• Article Data: 7

Chemical Properties

• CAS DataBase Reference: (E)-3-(3,5-difluorophenyl)acrylaldehyde(CAS DataBase Reference)
• NIST Chemistry Reference: (E)-3-(3,5-difluorophenyl)acrylaldehyde(405937-99-7)
• EPA Substance Registry System: (E)-3-(3,5-difluorophenyl)acrylaldehyde(405937-99-7)

Safety Data

• Hazardous Substances Data: 405937-99-7(Hazardous Substances Data)

Upstream product

• 32085-88-4 3,5-difluorobenzaldehyde 
• 75-07-0 acetaldehyde 
• 201230-82-2 carbon monoxide 
• 151361-87-4 1-ethynyl-3,5-difluorobenzene 
• 405937-98-6 (E)-3-(3,5-difluorophenyl)prop-2-en-1-ol 
• 2136-75-6 (triphenylphosphoranylidene)acetaldehyde 

Downstream Products

• 960006-18-2 3-{benzyl-[(E)-3-(3,5-difluoro-phenyl)-allyl]-amino}-propionitrile 
• 960006-19-3 rac-1-benzyl-4-(3,5-difluoro-benzyl)-pyrrolidine-3-carbonitrile 
• 1013421-31-2 3-(3,5-difluorophenyl)-2-phenylisoxazolidin-5-one 
• 857722-08-8 1,3-Difluoro-5-((1E,3E)-4-phenyl-buta-1,3-dienyl)-benzene 

Relevant articles and documents

INHIBITORS OF RECEPTOR INTERACTING PROTEIN KINASE I FOR THE TREATMENT OF DISEASE

Disclosed herein are compounds which inhibit RIPK1, pharmaceutical compositions, and methods of treatment of RIPK1-mediated diseases, such as neurodegenerative disorders, inflammatory disorders, and cancer.

Selective Rhodium-Catalyzed Hydroformylation of Terminal Arylalkynes and Conjugated Enynes to (Poly)enals Enabled by a π-Acceptor Biphosphoramidite Ligand

The hydroformylation of terminal arylalkynes and enynes offers a straightforward synthetic route to the valuable (poly)enals. However, the hydroformylation of terminal alkynes has remained a long-standing challenge. Herein, an efficient and selective Rh-catalyzed hydroformylation of terminal arylalkynes and conjugated enynes has been achieved by using a new stable biphosphoramidite ligand with strong π-acceptor capacity, which affords various important E-(poly)enals in good yields with excellent chemo- and regioselectivity at low temperatures and low syngas pressures.

PYRROLIDINE DERIVATIVES USEFUL AS BACE INHIBITORS

Novel 3-mono-, 3,4-di- and 3,4,4,-tri-substituted pyrrolidine compounds, these compounds for use in the diagnostic and therapeutic treatment of a warm-blooded animal, especially for the treatment of a disease (= disorder) that depends on the activity of b